Xoma (US) LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery

Phase 2

Completed

Conditions: Hypoglycemia

Interventions: Drug: XOMA 358 single dose level A
Drug: XOMA 358 multiple dose level 1
Drug: XOMA 358 single dose level B
Drug: XOMA 358 single dose level C

First Posted Date: 2016-05-13

Last Posted Date: 2021-05-21

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 20

Registration Number: NCT02772718

A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism

Phase 2

Completed

Conditions: Congenital Hyperinsulinism

Interventions: Drug: Cohort 1
Drug: Cohort 2
Drug: Cohort 3
Drug: Cohort 4

First Posted Date: 2015-11-13

Last Posted Date: 2017-02-06

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 10

Registration Number: NCT02604485

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Phase 3

Terminated

Conditions: Pyoderma Gangrenosum

Interventions: Drug: Placebo
Drug: gevokizumab open-label
Drug: gevokizumab

First Posted Date: 2014-12-29

Last Posted Date: 2016-04-27

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 9

Registration Number: NCT02326740

A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Phase 3

Terminated

Conditions: Pyoderma Gangrenosum

Interventions: Drug: gevokizumab

First Posted Date: 2014-12-17

Last Posted Date: 2016-04-27

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 15

Registration Number: NCT02318914

An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Phase 3

Terminated

Conditions: Pyoderma Gangrenosum

Interventions: Drug: Placebo
Drug: gevokizumab open-label
Drug: gevokizumab

First Posted Date: 2014-12-11

Last Posted Date: 2016-04-27

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 16

Registration Number: NCT02315417

Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand

Not Applicable

Completed

Conditions: Osteoarthritis

Interventions: Drug: gevokizumab

First Posted Date: 2014-11-18

Last Posted Date: 2015-02-19

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 312

Registration Number: NCT02293564

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

Phase 3

Terminated

Conditions: Behcet's Disease Uveitis

Interventions: Drug: Placebo
Drug: Gevokizumab

First Posted Date: 2014-10-08

Last Posted Date: 2015-12-29

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 4

Registration Number: NCT02258867

An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

Phase 3

Terminated

Conditions: Uveitis

Interventions: Drug: Dose 2 gevokizumab

First Posted Date: 2014-10-08

Last Posted Date: 2015-10-16

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 69

Registration Number: NCT02258854

The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease

Phase 2

Completed

Conditions: Autoimmune Inner Ear Disease

Interventions: Drug: gevokizumab

First Posted Date: 2013-09-25

Last Posted Date: 2016-02-03

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 10

Registration Number: NCT01950312

Locations: 🇺🇸
Long Island Jewish Medical Center, Hearing & Speech Center, New Hyde Park, New York, United States

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: Placebo
Drug: gevokizumab

First Posted Date: 2013-06-20

Last Posted Date: 2014-03-04

Lead Sponsor: XOMA (US) LLC

Target Recruit Count: 91

Registration Number: NCT01882491

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy